18:07 : Alkermes (ALKS) -3.9% AH after announcing Elan (ELN) plans to sell 13.9M ... -
Alkermes (ALKS) -3.9% AH after announcing Elan (ELN) plans to sell 13.9M shares through a secondary offering. Elan obtained a 25% stake in Alkermes as part of the latter's acquisition of the former's drug manufacturing business. ...
16:22 : FDA approves Alkermes/Amylin drug Bydureon -
BOSTON (MarketWatch) -- Partners Alkermes PLC and Amylin Pharmaceuticals announced Friday that the U.S. Food and Drug Administration has approved their drug Bydureon for the treatment of type 2 diabetes. The ...
08:43 : Alkermes reports loss following Elan merger -
Alkermes plc (Nasdaq: ALKS) reported a loss in its first financial reporting since the merger between Alkermes Inc. and Elan Drug Technologies was completed in September, largely due to merger-related ...
13:46 : Alkermes Completes Buy of Elan Drug Technologies -
Pharmaceutical company Alkermes Inc. on Friday completed its merger with Elan Drug Technologies, a drug formulation and manufacturing subsidiary of Elan Corp.